As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.
Immune system disorders and skin and subcutaneous tissue disorders
Allergic skin reactions such as dermatitis contact, dermatitis allergic, pruritus, erythema, eczema, rash, urticaria, skin irritation, and blisters. Hypersensitivity, anaphylactic reaction, and anaphylactic shock with respective laboratory and clinical manifestations including asthma syndrome, mild to moderate reactions potentially affecting skin, respiratory tract, gastrointestinal tract, and cardiovascular system, including symptoms such as rash, urticaria, edema, pruritus, and cardio- respiratory distress.
Eye disorder:
Frequency not known: Corneal erosion, epithelium defect/corneal injury, significant permanent visual impairment.
Cases of severe corneal erosion and permanent significant visual impairment due to inadvertent ocular exposure have been reported post- marketing, leading to some patients requiring corneal transplant (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.go.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.